Thursday, 5 November 2015
Pascal Soriot, Chief Executive Officer, commenting on the results said:
“I’m pleased with our continued progress as we focus on executing our plans across our growth platforms and pipeline. While we have more work to do on the submission of saxagliptin/dapagliflozin combination in Diabetes, the significant label update for Brilinta was accompanied by submission acceptances and accelerated reviews in cancer, respiratory diseases and lupus. In particular, our exciting Oncology portfolio maintained its momentum with four Priority Review and Fast Track designations as well as supportive data at key congresses.
Our financial performance in the year to date, including an 8% increase in Core EPS in the third quarter, underpinned today’s upgrade to full-year guidance. 2016 will be a pivotal year in our strategic journey as we face the impact of loss of exclusivity to Crestor in the US. Looking ahead however, the continued performance of our growth platforms and upcoming launches will combine with our increasing focus on costs and cash generation to help offset short-term headwinds and return AstraZeneca to sustainable growth.”
Downloads
Cautionary statement regarding forward looking statement (PDF 17kb)
Press release & pipeline update Q3 2015 (PDF 2012kb)
Results Presentation Q3 2015 (PDF 1987kb)
Clinical Trials Appendix Q3 2015 Update (PDF 2306kb)